Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $37.2 million.

  • Agios Pharmaceuticals' Accumulated Expenses rose 1173.93% to $37.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.2 million, marking a year-over-year increase of 1173.93%. This contributed to the annual value of $46.9 million for FY2024, which is 855.75% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Accumulated Expenses stood at $37.2 million for Q3 2025, which was up 1173.93% from $35.3 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Accumulated Expenses ranged from a high of $46.9 million in Q4 2024 and a low of $19.7 million during Q1 2022
  • Moreover, its 5-year median value for Accumulated Expenses was $30.4 million (2022), whereas its average is $31.0 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first crashed by 4120.75% in 2021, then skyrocketed by 4223.06% in 2023.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Accumulated Expenses stood at $32.0 million in 2021, then decreased by 5.06% to $30.4 million in 2022, then skyrocketed by 42.23% to $43.2 million in 2023, then increased by 8.56% to $46.9 million in 2024, then decreased by 20.58% to $37.2 million in 2025.
  • Its Accumulated Expenses was $37.2 million in Q3 2025, compared to $35.3 million in Q2 2025 and $20.8 million in Q1 2025.